Equities have greeted 2018 with a bang, but none more so than Korean pharmaceutical maker Celltrion Inc., which has piled on about 9 trillion won ($8.4 billion) of market value in just seven days.

Investment by renowned long-term investor affirms Bayer’s strategy

Human stem cells have shown potential in medicine as they can transform into various specialized cell types such as bone and cartilage cells. The current approach to obtain such specialized cells is to subject stem cells to specialized instructive protein molecules known as growth factors. However, use of growth factors in the human body can generate harmful effects including unwanted tissue growth, such as a tumor.

The advanced research Foundation (DRF) has established a laboratory to identify the likely directions of technological breakthroughs in the military field on the basis of Institute of immunology, reported RIA Novosti in the Fund.